as a way to prevent disease and death, but of course a polypill is a daily expense while vaccination provides long term protection. The question is whether a polypill is affordable in low-income countries.
Income -especially disposal income -is of course different between high-, middle-, and lowincome countries and could also be a partial explanation for the differences recorded in the PURE paper. 2 Previous reports from PURE suggest the availability and affordability of medical interventions is a reason for better control of hypertension in high income countries compared with low income countries. 5 Similarly, differences between rural and urban communities in terms of income might partly explain the differences in outcomes between the communities. Income in rural communities is generally less than in urban communities. Especially in low-income countries this might result in catastrophic healthcare expenditure. Even in middle-income countries it is not uncommon for medical costs to greatly exceed total income. 6 Previous reports from PURE have indicated that even a drug as cheap and available as aspirin is 7-times less likely to be used in low-income countries than in highincome countries. 7 Data on incomes and costs of drugs have been collected in the PURE study and these data might identify the communities most lacking in affordable medicines.
What might be done if, as anticipated from casual observation, drugs are too expensive to be affordable to a large and needy population? The pharmaceutical industry has provided antiretroviral drugs at low price and this has been a valuable component in the fight against HIV. It would be unreasonable, however, to ask pharmaceutical companies to provide all their proprietary drugs at (near) cost price. This would stifle investment and ultimately adversely influence health-care for allespecially in poorer countries. Governments in low-income countries might be able (with targeted financial aid) to afford to subsidise provision of drugs at affordable prices -especially if bought in bulk through a coordinating international organisation. Or perhaps international aid might be used to help governments to establish production facilities within countries for generic (or licensed) drugs, or a polypill. Some might argue that the focus should be on education and promotion of better lifestyles for prevention of cardiovascular disease. There might ultimately be a place for some such interventions, but in the short-and medium-term it seems that provision of affordable drugs is a key to preventing or ameliorating cardiovascular disease and saving lives. However, when even aspirin is not universally affordable, new ways of providing access to drugs is needed.
